Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Next Previous
X
Search
Trial Profile

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quisovalimab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 08 Mar 2021 According to a Cerecor media release, initial data is expected in the second quarter
    • 01 Nov 2018 According to an Aevi Genomic Medicine media release, the Company has not yet enrolled any patients into this trial and expects to enrol a small number of patients by the end of the first quarter of 2019. Initial data is expected by mid-year 2019.
    • 13 Mar 2018 According to an Aevi Genomic Medicine media release, the company is initiating three additional sites in an effort to enhance enrollment and data expected by year-end 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top